Overview of Maxpro (Cefixime)

Quick Facts

Property	Description
Active ingredient	Cefixime
Form	Oral (Tablet, Capsule, Suspension)
Pharmacological class	Third-Generation Cephalosporin Antibiotic
Common use	Systemic bacterial infection
Origin	Semisynthetic

Maxpro is the trade name for the active drug Cefixime, which is a prescription-only medicine primarily used to resolve bacterial infections throughout the body. Cefixime belongs to the class of semisynthetic antibiotics known as cephalosporins, specifically categorized as a third-generation agent within that group. This pharmacological classification signifies its broad ability to effectively target and eliminate a wide array of susceptible bacteria.

Cefixime: Identity, Differentiation, and General Purpose

Cefixime is fundamentally a broad-spectrum cephalosporin antibiotic, derived semisynthetically through the chemical modification of a natural compound. Its chemical structure is that of a beta-lactam antibiotic, which is critical to its function, allowing it to act as a bactericidal agent that directly destroys the bacterial cell wall. Cefixime exhibits high efficacy against various common bacterial pathogens, making it a clinically recognized choice for treating systemic infections.

The composition centers entirely on the single active ingredient, Cefixime, typically provided as its trihydrate salt. As an INN (International Nonproprietary Name), Cefixime is also marketed under other popular brand names globally, such as Suprax. Maxpro specifically provides an orally administered option for managing infections in both adult and pediatric populations, differentiated by the availability of a flavored oral suspension form.

Available Forms and Administration Route

The drug is available solely as an oral formulation, designed for effective absorption through the digestive system, a key feature that simplifies treatment compared to injectable alternatives. The official pharmaceutical preparations include film-coated tablets, capsules, and a powder for oral suspension that is reconstituted into a liquid form. The availability of these different oral forms ensures the medicine can be administered across various patient groups, maintaining consistent therapeutic delivery.

Regulatory References

Cefixime: MedlinePlus Drug Information

What side effects are possible with Maxpro (Cefixime)?

Possible Side Effects and Safety Information

The safety profile of Cefixime, a third-generation cephalosporin, is officially classified based on reports from clinical trials and post-marketing surveillance, detailing adverse reactions by frequency and physiological system. All safety information is based strictly on government regulatory documents.

Frequency-Classified Adverse Reactions

The most Common adverse reactions (reported ge 1% in US clinical trials) relate predominantly to the gastrointestinal system, including diarrhea, nausea, abdominal pain, and loose/frequent stools. Reactions reported with an incidence less than 2% include vomiting, transient elevations in liver enzymes, headache, and dizziness.

Serious Adverse Reactions and Safety Constraints

The official label mandates attention to serious, though infrequent, risks. These include severe hypersensitivity reactions (such as anaphylaxis), and severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Acute renal failure and life-threatening Clostridium difficile-associated diarrhea (CDAD) are also documented as serious potential adverse effects.

Cefixime is contraindicated in individuals with known hypersensitivity to any cephalosporin antibiotic. Caution is advised for patients with a history of penicillin hypersensitivity due to the potential for cross-allergenicity, and for those with pre-existing gastrointestinal disease.

Population-Specific Safety Notes

Specific safety considerations apply to certain populations. Individuals with markedly impaired renal function are at a documented risk of developing encephalopathy (seizures, confusion); caution is required in this group. Safety and efficacy have not been established in infants under six months of age. The onset of gastrointestinal symptoms like colitis may occur during or following antibacterial therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Cefixime may present with manifestations of encephalopathy, including convulsions (seizures), confusion, impaired consciousness, and movement disorders, as documented in regulatory information. While adverse reactions at very high doses may not differ significantly from those at standard therapeutic doses, the potential for serious central nervous system effects requires adherence to official emergency protocol.

Regulator-Mandated Emergency Actions

Immediate medical attention is required for suspected overdosage. When severe symptoms occur, such as collapse, a seizure, or trouble breathing, the official regulatory guidance mandates calling emergency services and contacting the poison control helpline immediately.

Management and Risk Factors

No specific antidote exists for Cefixime overdosage. Therefore, management is strictly symptomatic and supportive, and may include procedures such as gastric lavage. A crucial regulatory note is that Cefixime is not removed in significant quantities from the circulation by hemodialysis or peritoneal dialysis. Furthermore, regulatory labeling highlights an increased risk of neurotoxicity, including encephalopathy and seizures, particularly in patients with renal impairment.

Therapeutic Uses of Maxpro (Cefixime)

What Maxpro (Cefixime) Treats: Main Uses and Benefits

Maxpro (Cefixime) is an established cephalosporin antibiotic commonly used to help with various bacterial infections across different body systems. It is applied in addressing the underlying condition, and it contributes to easing the patient's symptomatic burden. The medication is applied in contexts involving a number of conditions marked by increased physiological stress.

Symptom Management and Therapeutic Benefit

Maxpro is commonly used to help with acute or recurrent infections such as Otitis Media (ear infection), Tonsillitis, Pharyngitis, Bronchitis, and Uncomplicated Urinary Tract Infections (UTIs). The medication is relevant in contexts marked by increased discomfort where symptoms related to physical discomfort (like ear pain or sore throat) and functional stress (such as painful urination) are present. This therapeutic approach supports general well-being during symptomatic phases and may contribute to improved day-to-day comfort by helping to address symptom clusters that may become intense or disruptive.

Quick Fact: Support for Acute Discomfort

Property	Description
Primary Role	Support for conditions involving bacterial cause
Symptom Focus	Pain, fever, and functional distress from inflammation
Benefit	Contributes to easing the overall symptom load
Typical Scenario	Out-patient treatment of acute symptomatic episodes

Regulatory References

NIH DailyMed official Cefixime indications

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Maxpro (Cefixime) — Official Regulatory Information

The eligibility for Maxpro (Cefixime) is strictly defined by regulatory documents, which establish clear criteria for use based on patient characteristics and existing conditions.

Populations for Whom Use is Contraindicated

Use is prohibited for patients with a documented history of hypersensitivity to Cefixime, other cephalosporin antibiotics, or a severe, immediate reaction to penicillin or any other beta-lactam antibiotic.

Age-Based Eligibility

Cefixime is officially approved for use in adults, adolescents, and pediatric patients six months of age or older. Safety and efficacy have not been established in children younger than six months.

Conditional and Restricted Use

Use is restricted for certain populations and requires special consideration:

Renal Function: Patients with impaired renal function (kidney disease) must be evaluated and managed under restricted conditions.
Comorbidities: Use is conditional for patients with a history of colitis or those using anticoagulation therapy.
Pregnancy & Lactation: The medicine is restricted during pregnancy and lactation, permitted only when use is determined to be clearly needed by the prescribing physician.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Officially documented interaction patterns for Maxpro (Cefixime) involve pharmacodynamic effects on the blood coagulation system and potential alterations to the exposure of certain co-administered medicines. The drug is predominantly eliminated unchanged by the kidneys and is not reported to have clinically significant interactions via the major CYP450 enzyme systems.

Drug–Drug Interaction Patterns

Interacting Product Category	Officially Documented Outcome
Coumarin-Type Anticoagulants (e.g., Warfarin)	May enhance the anticoagulant effect, resulting in a documented increase in prothrombin time.
Carbamazepine	Co-administration has been reported to cause elevated Carbamazepine plasma concentrations (increased exposure).
Live Bacterial Vaccines (e.g., Oral Typhoid)	May reduce the therapeutic efficacy of the vaccine due to antibacterial activity.
Potentially Nephrotoxic Agents	Co-administration requires caution due to an additive risk of nephrotoxicity (e.g., with aminoglycosides or high-dosed loop diuretics).

Timing and Substance Notes

The antibiotic activity of Cefixime necessitates that the oral live Typhoid vaccine should not be administered during and for at least three days before and after treatment. Cefixime may be taken with or without food, as no clinically significant interaction mandating specific timing relative to meals is documented in the labeling. Patients with renal or hepatic impairment are identified as having an increased risk for the coagulation effects when Cefixime is co-administered with anticoagulants.

Mechanism of Action

Cefixime functions as a bactericidal agent by executing a highly specific molecular attack on the structures essential for bacterial survival. Its entire action profile is derived from the covalent inhibition of bacterial enzyme systems.

Molecular Targeting of Penicillin-Binding Proteins

Cefixime’s beta-lactam structure irreversibly binds to and inactivates the bacterial enzymes known as Penicillin-Binding Proteins (PBPs) . These enzymes, specifically transpeptidases, are essential for constructing the rigid bacterial cell wall. This molecular interaction initiates a disruption of the pathogen's structure.

Causal Cascade Leading to Cell Lysis

By blocking the final peptidoglycan cross-linking step in the cell wall synthesis pathway, Cefixime compromises the cell's structural integrity, causing it to lose its stability against internal osmotic pressure. This culminates in rapid cell lysis (rupture), resulting in the death of susceptible bacterial cells.

Structural Stability and Mechanistic Limitations

Cefixime retains its PBP-inhibitory action due to greater structural stability against many common beta-lactamases. However, this mechanism is constrained by bacterial adaptations, including the presence of Extended-Spectrum Beta-Lactamases (ESBLs) or mutations in the PBP target itself.

Dosage and Administration Information

Administration and Dosing Protocol

Maxpro (Cefixime) is an antibiotic restricted to oral administration only, available as tablets, capsules, and a powder for oral suspension. The official instructions for use are highly structured, defining the precise dose, frequency, and administration conditions based on regulatory standards.

Official Administration Guidelines

Instruction	Detail
Route of Administration	Oral administration only.
Standard Adult Dose	400 mg once daily, or the dose may be divided and administered as 200 mg every 12 hours. Uncomplicated gonorrhea requires a single 400 mg oral dose.
Timing in Relation to Meals	May be administered without regard to food.
Preparation Requirements	The powder for oral suspension must be reconstituted with water as directed and requires shaking well before each use.
Pediatric Rules	Dosing is calculated based on body weight at 8 mg/kg/day. Dose modification is mandatory for adults with renal impairment (CrCl less than 60 mL/min).
Missed Dose Rule	If a dose is missed, it should be taken as soon as possible, or skipped if near the next dose time, to avoid doubling the dose.
Special Conditions	Treatment for Streptococcus pyogenes requires a minimum course of 10 days. The oral suspension must be used for Otitis Media due to formulation-specific absorption, and substitution with tablets is not advised.

Resulting Procedural Structure

The protocol defines the oral route as the sole administration method and sets precise numerical doses for adults and weight-based calculations for children. These official usage guidelines require a compulsory dose reduction for patients with kidney function impairment and impose minimum duration requirements for specific infections to ensure complete therapeutic coverage.

Recent Clinical Evidence

Research evidence / Overview of Studies for Maxpro (Cefixime)

Evidence for Use in Acute Infections

Research has examined Cefixime in the context of various acute infections, using randomized controlled trials (RCTs) and comparative clinical studies. For Acute Exacerbations of Chronic Bronchitis (AECB), studies monitored outcomes reflecting daily functioning and bacteriological status in adults over defined time intervals.

Cefixime was also evaluated for Otitis Media and Pharyngitis/Tonsillitis in pediatric populations six months of age and older. While research examined the short-term bacteriological status, the evidence is limited for infections caused by certain pathogens like S. pyogenes due to small sample sizes in key trials. For Uncomplicated Urinary Tract Infections (uUTIs), short-term RCTs explored symptom changes and monitored bacterial clearance in both adult and pediatric patients.

Specific Communicable Infections

Clinical trials examined short-term microbiological eradication rates for Uncomplicated Gonorrhea (UG). However, surveillance data shows patterns related to decreasing bacterial susceptibility over time in certain regions. Evidence suggests findings were mixed regarding sustained, uniform susceptibility globally.

Research Gaps and Limitations

The evidence base is primarily focused on acute episodes, meaning follow-up durations were limited (typically days or weeks). Research describes that long-term effects are not fully established across most indications. For instance, regulatory documentation notes that data is unavailable to establish the long-term role of the medicine in the subsequent prevention of complications related to S. pyogenes infection. Although examined in adult and pediatric populations, data for certain groups remain insufficient, and results apply only to the specific populations studied. Certainty remains low regarding the universal application of some earlier trial findings across all geographical areas due to varying evidence quality.

Key Studies & References

Cefixime capsule - Official Labeling and Indications

Frequently Asked Questions (FAQ)

Common questions about Maxpro (Cefixime) (FAQ)

Q: What is the general recommended duration for a course of Maxpro (Cefixime) treatment?

A: The duration of a course of Maxpro (Cefixime) is determined by the specific infection and the official treatment guidelines. While some conditions may require a single dose, official protocol for certain infections requires a minimum duration, such as 10 days, to ensure the elimination of the infecting bacteria.

Q: What are the warning signs of a serious allergic reaction to Maxpro (Cefixime)?

A: Official safety documents describe serious allergic reactions, including anaphylaxis. These can involve symptoms like swelling of the face, throat, or tongue, and difficulty breathing. Severe reactions also include documented skin conditions that involve blistering or peeling.

Q: Is Maxpro (Cefixime) generally considered acceptable for use during pregnancy?

A: Official documentation states that Maxpro (Cefixime) should only be used during pregnancy if the healthcare professional determines that the need for the medicine is clearly established. Official guidance notes that studies in pregnant women are limited, which informs the cautious use.

Q: What information is available regarding the use of Maxpro (Cefixime) while breastfeeding?

A: Regulatory information confirms that Cefixime is excreted into breast milk in small amounts. Official guidance requires consideration of the drug’s importance to the mother versus any potential effects on the nursing infant.

Q: What is a 'superinfection' and how is it related to Maxpro (Cefixime) use?

A: The use of Maxpro (Cefixime) may lead to the overgrowth of non-susceptible organisms, which is a type of complication known as a superinfection. A serious example of this that is documented in the safety label is Clostridium difficile-associated diarrhea (CDAD).

Q: What level of severity of diarrhea should prompt immediate contact with a healthcare professional?

A: Official guidance advises that diarrhea that is persistent or severe should be reported. Diarrhea that is accompanied by blood may be a sign of a serious, documented adverse effect such as C. difficile infection.

Q: How is Maxpro (Cefixime) different from penicillin antibiotics?

A: Maxpro (Cefixime) is officially classified as a third-generation cephalosporin, which is a different antibiotic class than penicillins. Despite the difference in classification, both types of medicines belong to the broader family of beta-lactam antibiotics.

Q: Does Maxpro (Cefixime) treat infections caused by viruses, like the common cold or flu?

A: Official drug information states that Cefixime is an antibiotic prescribed only for the treatment of bacterial infections. It is not indicated for and will not work against viral infections, such as the common cold or flu.

Q: What specific type of bacteria is Maxpro (Cefixime) designed to kill?

A: Regulatory documents indicate that Maxpro (Cefixime) is intended to target a broad range of susceptible bacteria, including specific types of Gram-positive and Gram-negative organisms. The full range of susceptible bacteria is detailed in the official prescribing information.

Q: Why is it important to complete the entire course of Maxpro (Cefixime) even if symptoms improve quickly?

A: According to official regulatory guidance, completing the full course of Cefixime is important to support the full elimination of the infecting bacteria. Not completing the course may increase the potential for the development of drug-resistant bacteria.

Q: Can Maxpro (Cefixime) be taken at the same time as antacids?

A: Official pharmacokinetic studies found no significant alteration to Cefixime absorption when taken with antacids that do not contain aluminum or magnesium. Separation is generally not required for these specific types of antacids.

Q: Can people with pre-existing liver problems take Maxpro (Cefixime)?

A: Official product information advises caution when Maxpro (Cefixime) is administered to patients with pre-existing hepatic (liver) disease. Unlike kidney impairment, a specific dose adjustment based solely on liver function is not typically mandated.

Q: Does Maxpro (Cefixime) cause increased bleeding or bruising in some individuals?

A: Regulatory safety data has officially associated Cefixime use with increases in prothrombin time (a measure of blood clotting). This effect suggests that cautious monitoring of bleeding indicators may be required, especially when co-administered with blood-thinning agents.

Q: Can Maxpro (Cefixime) interfere with the results of a urine sugar test for diabetes?

A: Official product labeling contains a specific warning that Cefixime can interfere with certain urine glucose tests used to monitor diabetes. It may result in a false-positive reading when using methods like Clinitest, Benedict's solution, or Fehling's solution.

Q: Does Maxpro (Cefixime) contain any known substances that interact with Phenylketonuria (PKU)?

A: The official description of the medicine notes that the oral suspension form of Maxpro (Cefixime) is formulated to contain phenylalanine. This ingredient must be considered by patients with the metabolic condition Phenylketonuria (PKU).

Q: What is the difference between the oral capsule and the chewable tablet forms of Maxpro (Cefixime)?

A: Regulatory guidelines specify that the oral suspension is the required formulation for treating Otitis Media in pediatric patients due to known differences in how the body absorbs it. Official instructions advise against substituting tablets or capsules for the suspension in this specific indication.

Q: Is a loss of appetite a known side effect of Maxpro (Cefixime)?

A: Yes, official post-marketing surveillance reports have listed a loss of appetite, referred to as anorexia, as an uncommon or rare adverse reaction associated with Maxpro (Cefixime).

Q: What should be done if an infection does not seem to respond to Maxpro (Cefixime)?

A: According to official guidance, if the symptoms of the infection do not begin to improve or if the condition appears to worsen, patients should seek guidance from their healthcare provider regarding the treatment plan.

Q: Is Maxpro (Cefixime) associated with joint or muscle aches?

A: Official regulatory documents indicate that joint pain has been reported as a rare or very rare side effect associated with Cefixime use.

Q: Is it normal to experience white patches in the mouth while on Maxpro (Cefixime)?

A: Official safety information states that the use of antibiotics, including Maxpro (Cefixime), can potentially lead to the overgrowth of non-susceptible organisms. This is a form of superinfection that may result in oral thrush, often characterized by white patches in the mouth.

Q: Can Maxpro (Cefixime) affect a patient's sleep patterns or cause unusual tiredness?

A: Official post-marketing surveillance data has documented that unusual tiredness, known as fatigue, is reported as an uncommon adverse reaction associated with this medicine. However, there is no specific regulatory mention of effects on general sleep patterns.

Q: Can Maxpro (Cefixime) lead to reduced white blood cell counts?

A: Official regulatory safety data documents that reduced white blood cell counts (leukopenia) and other changes in blood cell levels have been reported as rare to very rare adverse reactions associated with Cefixime.

How should Maxpro (Cefixime) be stored and disposed of?

How to Store and Dispose of Maxpro (Cefixime)

Official regulatory information defines specific storage, stability, and disposal requirements for Maxpro (Cefixime).

Official Storage and Stability Constraints

Product Form	Temperature Requirement	Stability Limit
Tablets, Capsules, Unreconstituted Powder	Controlled Room Temperature (20 C to 25 C)	Until Expiration Date
Reconstituted Liquid Suspension	Room Temperature or Refrigerated (2 C to 8 C)	Discard After 14 Days

All forms must be stored in a tightly closed container and protected from excessive moisture. It is strictly required that the medication be kept from freezing; this applies specifically to the prepared liquid suspension. Store Maxpro out of the sight and reach of children.

Disposal Requirements

Unused, expired, or leftover liquid suspension after 14 days should not be kept. Regulatory guidelines advise disposing of the product according to local regulations, often by asking a pharmacist or healthcare provider about returning it to an approved waste disposal plant.

Maxpro (Cefixime)